State Board of Administration of Florida Retirement System Sells 1,269 Shares of Illumina, Inc. (ILMN)
State Board of Administration of Florida Retirement System reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 0.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 218,984 shares of the life sciences company’s stock after selling 1,269 shares during the period. State Board of Administration of Florida Retirement System owned 0.15% of Illumina worth $43,622,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. Dupont Capital Management Corp bought a new position in shares of Illumina in the 3rd quarter worth $153,000. Andra AP fonden lifted its holdings in Illumina by 12.3% during the third quarter. Andra AP fonden now owns 7,300 shares of the life sciences company’s stock worth $1,454,000 after acquiring an additional 800 shares in the last quarter. Howland Capital Management LLC bought a new position in Illumina during the third quarter worth about $1,058,000. Essex Investment Management Co. LLC lifted its holdings in Illumina by 6.8% during the third quarter. Essex Investment Management Co. LLC now owns 12,433 shares of the life sciences company’s stock worth $2,477,000 after acquiring an additional 792 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its holdings in Illumina by 110.1% during the third quarter. Canada Pension Plan Investment Board now owns 19,210 shares of the life sciences company’s stock worth $3,827,000 after acquiring an additional 10,068 shares in the last quarter. Institutional investors and hedge funds own 93.04% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up $5.17 during trading hours on Friday, hitting $213.99. The stock had a trading volume of 633,347 shares, compared to its average volume of 818,844. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $31,242.54, a PE ratio of 62.57, a PEG ratio of 3.53 and a beta of 0.74. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $214.50.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company’s revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.97 earnings per share. analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current year.
In other news, CAO Michel Bouchard sold 616 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,200.00. Following the sale, the chief accounting officer now directly owns 15,161 shares of the company’s stock, valued at $3,032,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $205.71, for a total value of $29,827.95. The disclosure for this sale can be found here. In the last 90 days, insiders sold 168,026 shares of company stock valued at $34,234,070. Insiders own 1.60% of the company’s stock.
ILMN has been the topic of several recent analyst reports. Barclays PLC lifted their target price on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price on the stock in a report on Friday, October 27th. Canaccord Genuity reiterated a “buy” rating and set a $230.00 target price (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. BidaskClub lowered Illumina from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $226.00 target price (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $200.88.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.